Argentina vs Colombia: Average cost of multi drug-resistant tuberculosis treatment
Argentina
1,547 constant 2022 US$
in 2024
Colombia
1,528 constant 2022 US$
in 2024
Argentina rank
31st
Colombia rank
32nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Argentina
- Colombia
How they compare
Argentina currently reports 1,547 constant 2022 US$ against 1,528 constant 2022 US$ in Colombia, a difference of 19 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Argentina ahead.
Argentina ranks 31st and Colombia ranks 32nd of 92 countries.
Argentina has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Argentina | Colombia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,035 constant 2022 US$ | 2,500 constant 2022 US$ | 534.67 constant 2022 US$ | Argentina |
| 2020s | 1,334 constant 2022 US$ | 953 constant 2022 US$ | 381.4 constant 2022 US$ | Argentina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Argentina or Colombia?
- Argentina, at 1,547 constant 2022 US$ against 1,528 constant 2022 US$ in Colombia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Argentina and Colombia?
- 19 constant 2022 US$, with Argentina ahead.
- How many years of comparable data are there for Argentina and Colombia?
- 8 years are reported by both, from 2017 to 2024.
- How do Argentina and Colombia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Argentina ranks 31st and Colombia ranks 32nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.